Lamivudină/Zidovudină Aurobindo

Lamivudine and Zidovudine, the active ingredients in Lamivudină/Zidovudină Aurobindo, are nucleoside reverse transcriptase inhibitors presented as oral tablets for oral use. They treat HIV-1 infection in both adults and children as part of combination antiretroviral therapy.

GNH USA supplies Lamivudină/Zidovudină Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability, regulatory compliance, and dedicated technical support throughout the supply chain.

Lamivudină/Zidovudină is employed in antiretroviral therapy that targets HIV-1 replication.

- HIV-1 infection in adults: reduces viral load and helps restore immune function. - HIV-1 infection in children: improves growth parameters and decreases opportunistic infections. - Treatment‑experienced HIV-1 infection: used as part of salvage regimens when resistance has developed. - Prevention of mother‑to‑child transmission: incorporated into combination prophylaxis to lower transmission risk during pregnancy and delivery.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Fatigue: generalised tiredness. - Anemia: reduced red blood cell count. - Neutropenia: lowered neutrophil levels. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Severe liver toxicity: hepatic enzyme elevation or failure. - Lactic acidosis: accumulation of lactate leading to metabolic acidosis. - Severe neutropenia: risk of opportunistic infections. - Hypersensitivity reactions: rash, fever, or organ involvement. - Pancreatitis: inflammation of the pancreas. - Bone marrow suppression: pancytopenia affecting multiple cell lines.

Patients should be monitored for safety and efficacy before and during therapy.

- Blood count monitoring: regularly assess haemoglobin and neutrophil levels. - Liver function assessment: evaluate hepatic enzymes prior to initiation. - Renal function evaluation: check creatinine clearance in patients with kidney disease. - Adherence counseling: emphasize the importance of consistent dosing. - Hypersensitivity avoidance: discontinue if severe allergic reactions occur. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudină/Zidovudină may interact with several concomitant medications.

Major Interactions (Avoid): - Didanosine: increased risk of peripheral neuropathy and pancreatitis. - Stavudine: heightened mitochondrial toxicity leading to lactic acidosis. - Alcohol: potentiates hepatotoxic effects.

Moderate Interactions (Monitor Closely): - Rifampin: induces metabolism, reducing drug concentrations. - Antacids containing aluminium or magnesium: may impair absorption. - Protease inhibitors (e.g., ritonavir): alter plasma levels, requiring dose adjustment.